, et al. Global variation in patterns of care and time to initial treatment for breast,cervical,and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories[J]. Lancet, 2025, 406(10517):2325-2348. DOI:10.1016/S0140-6736(25)01383-2.

Cited in this article [1]

[2]	Bensing J. Bridging the gap. The separate worlds of evidence-based medicine and patient-centered medicine[J]. Patient Educ Couns, 2000, 39(1):17-25. DOI:10.1016/s0738-3991(99)00087-7. Cited in this article [1]

[3]	Kordowitzki P, Lange B, Elias KM, et al. Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer[J]. CA Cancer J Clin, 2025, 75(5):436-460. DOI:10.3322/caac.70008. Cited in this article [1]

[4]	Fusco R, Granata V, Simonetti I, et al. An informative review of radiomics studies on cancer imaging: the main findings,challenges and limitations of the methodologies[J]. Curr Oncol, 2024, 31(1):403-424. DOI:10.3390/curroncol31010027. Cited in this article [1]

[5]	Thorel L, Perréard M, Florent R, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology[J]. Exp Mol Med, 2024, 56(7):1531-1551. DOI:10.1038/s12276-024-01272-5. Cited in this article [1]

[6]	Shi W, Zhang Z, Xu X, et al. Single-cell and spatial transcriptomics integration: new frontiers in tumor microenvironment and cellular communication[J]. Front Immunol, 2025,16:1649468. DOI:10.3389/fimmu.2025.1649468. Cited in this article [1]

[7]	中国研究型医院学会妇产科学专业委员会. 子宫内膜癌分子分型临床应用中国专家共识(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(6):638-644. DOI:10.19538/j.fk2024060114. Cited in this article [1]

[8]

Ptter

, Tanderup

, Schmid

, et al. 2638 EMBRACEⅡ-a multicenter prospective interventional cohort study on IGRT-IMRT+cisplatin+MR-IGABT in locally advanced cervix cancer: overall results[J]. Radiotherapy & Oncology, 2025, 206(Sup1): S837-S840.DOI:10.1016/S0167-8140(25)01194-6.

Cited in this article [1]

[9]

Al-Hammouri

, Almeida-Magana

, Soukup

, et al. Implementation of streamlining measures in selecting and prioritising complex cases for the cancer multidisciplinary team meeting: a mini review of the recent developments[J]. Front Health Serv, 2024,4:1340320. DOI:10.3389/frhs.2024.1340320.

Cited in this article [1]

[10]	Williams GJ, Thompson JF. Management changes and survival outcomes for cancer patients after multidisciplinary team discussion; a systematic review and meta-analysis[J]. Cancer Treat Rev, 2025,139:102997. DOI:10.1016/j.ctrv.2025.102997. Cited in this article [1]

[11]	Sedrak MS, Freedman RA, Cohen HJ, et al. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions[J]. CA Cancer J Clin, 2021, 71(1):78-92. DOI:10.3322/caac.21638. Cited in this article [1]

[12]	Rousseau A, Géraud A, Geiss R, et al. Safety of solid oncology drugs in older patients: a narrative review[J]. ESMO Open, 2024, 9(11):103965. DOI:10.1016/j.esmoop.2024.103965. Cited in this article [1]

[13]	Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy:ASCO guideline for geriatric oncology[J]. J Clin Oncol, 2018, 36(22):2326-2347. DOI:10.1200/JCO.2018.78.8687. Cited in this article [1]

[14]	Dotan E, Walter LC, Browner IS, et al. NCCN Guidelines^® Insights:Older Adult Oncology,Version 1.2021[J]. J Natl Compr Canc Netw, 2021, 19(9):1006-1019. DOI:10.6004/jnccn.2021.0043. Cited in this article [1]

[15]	Idasiak-Piechocka I, Lewandowski D, Świgut W, et al. Effect of hypoalbuminemia on drug pharmacokinetics[J]. Front Pharmacol, 2025,16:1546465. DOI:10.3389/fphar.2025.1546465. Cited in this article [1]

[16]

Ansmann

, Pfaff

. Providers and patients caught between standardization and individualization: individualized standardization as a solution comment on "(re) making the procrustean bed? standardization and customization as competing logics in healthcare"[J]. Int J Health Policy Manag, 2018, 7(4):349-352. DOI:10.15171/ijhpm.2017.95.

Cited in this article [1]

[17]	Engels FK, Loos WJ, van der Bol JM, et al. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study[J]. Clin Cancer Res, 2011, 17(2):353-362. DOI:10.1158/1078-0432.CCR-10-1636. Cited in this article [1]

[18]	Xie W, Huang H, Xiao S, et al. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases:A meta-analysis of observational studies[J]. Autoimmun Rev, 2020, 19(12):102687. DOI:10.1016/j.autrev.2020.102687. Cited in this article [1]

[19]	Zhang K, Kong X, Li Y, et al. PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases[J]. Front Pharmacol, 2022,13:854967. DOI:10.3389/fphar.2022.854967. Cited in this article [1]

[20]	Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Guidelines^®Insights: Management of Immunotherapy-Related Toxicities,Version 2.2024[J]. J Natl Compr Canc Netw, 2024, 22(9):582-592. DOI:10.6004/jnccn.2024.0057. Cited in this article [1]

[21]	Sánchez-Bayona R, Catalán C, Cobos MA, et al. Pharmacogenomics in solid tumors: a comprehensive review of genetic variability and its clinical implications[J]. Cancers (Basel), 2025, 17(6):913. DOI:10.3390/cancers17060913. Cited in this article [1]

[22]	Purandare N, Ruiloba F, Nguyen-Hoang L, et al. Cancer and fertility management:FIGO best practice advice[J]. Int J Gynaecol Obstet, 2025, 171(1):32-44. DOI:10.1002/ijgo.70426. Cited in this article [1]

[23]	McHenry A, Devereaux K, Ryan E, et al. Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma:prognostic relevance among low-and high-stage tumours[J]. Histopathology, 2024, 85(4):614-626. DOI:10.1111/his.15232. Cited in this article [1]

[24]	Moreno-Moreno E, Caniego-Casas T, Carretero-Barrio I, et al. Histologic and molecular type changes in endometrial cancer recurrences in comparison with their corresponding primary tumors[J]. Am J Surg Pathol, 2024, 48(12):1580-1587. DOI:10.1097/PAS.0000000000002308. Cited in this article [1]

[25]	狄文, 金明珠. 人工智能技术在妇产科应用中的思考与挑战[J]. 中国实用妇科与产科杂志, 2025, 41(1):11-14. DOI:10.19538/j.fk2025010104. Cited in this article [1]

[26]	狄文, 张楠. 卵巢恶性肿瘤诊疗观念的思考与挑战[J]. 中国实用妇科与产科杂志, 2024, 40(11):1057-1060. DOI:10.19538/j.fk2024110101. Cited in this article [1]